Fortress Biotech has announced that the U.S. Patent and Trademark Office (USPTO) has given Notices of Allowance to Avenue for two patent applications that cover methods of administration for its lead product candidate intravenous (IV) tramadol. These patent applications are continuation patent applications of issued U.S. patent 8,895,622, titled Intravenous Administration of Tramadol. The patents to be issued from these allowed applications, which carry a patent term to at least 2032, contain claims directed to Avenue's proposed administration of IV tramadol for Phase III development. Issuance of both of these patents is expected early in the first quarter of 2017. These patent applications fall under Avenue's licensing agreement with Revogenex Ireland Ltd.